BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

367 related articles for article (PubMed ID: 26423550)

  • 1. Age in antiretroviral therapy programmes in South Africa: a retrospective, multicentre, observational cohort study.
    Cornell M; Johnson LF; Schomaker M; Tanser F; Maskew M; Wood R; Prozesky H; Giddy J; Stinson K; Egger M; Boulle A; Myer L;
    Lancet HIV; 2015 Sep; 2(9):e368-75. PubMed ID: 26423550
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Twelve-year mortality in adults initiating antiretroviral therapy in South Africa.
    Cornell M; Johnson LF; Wood R; Tanser F; Fox MP; Prozesky H; Schomaker M; Egger M; Davies MA; Boulle A;
    J Int AIDS Soc; 2017 Sep; 20(1):21902. PubMed ID: 28953328
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gender differences in survival among adult patients starting antiretroviral therapy in South Africa: a multicentre cohort study.
    Cornell M; Schomaker M; Garone DB; Giddy J; Hoffmann CJ; Lessells R; Maskew M; Prozesky H; Wood R; Johnson LF; Egger M; Boulle A; Myer L;
    PLoS Med; 2012; 9(9):e1001304. PubMed ID: 22973181
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment guidelines and early loss from care for people living with HIV in Cape Town, South Africa: A retrospective cohort study.
    Katz IT; Kaplan R; Fitzmaurice G; Leone D; Bangsberg DR; Bekker LG; Orrell C
    PLoS Med; 2017 Nov; 14(11):e1002434. PubMed ID: 29136014
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Excess mortality associated with mental illness in people living with HIV in Cape Town, South Africa: a cohort study using linked electronic health records.
    Haas AD; Ruffieux Y; van den Heuvel LL; Lund C; Boulle A; Euvrard J; Orrell C; Prozesky HW; Tiffin N; Lovero KL; Tlali M; Davies MA; Wainberg ML;
    Lancet Glob Health; 2020 Oct; 8(10):e1326-e1334. PubMed ID: 32971055
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Task shifting of antiretroviral treatment from doctors to primary-care nurses in South Africa (STRETCH): a pragmatic, parallel, cluster-randomised trial.
    Fairall L; Bachmann MO; Lombard C; Timmerman V; Uebel K; Zwarenstein M; Boulle A; Georgeu D; Colvin CJ; Lewin S; Faris G; Cornick R; Draper B; Tshabalala M; Kotze E; van Vuuren C; Steyn D; Chapman R; Bateman E
    Lancet; 2012 Sep; 380(9845):889-98. PubMed ID: 22901955
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Time to eligibility for antiretroviral therapy in adults with CD4 cell count > 500 cells/μL in rural KwaZulu-Natal, South Africa.
    McGrath N; Lessells RJ; Newell ML
    HIV Med; 2015 Sep; 16(8):512-8. PubMed ID: 25959724
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adolescent HIV treatment in South Africa's national HIV programme: a retrospective cohort study.
    Maskew M; Bor J; MacLeod W; Carmona S; Sherman GG; Fox MP
    Lancet HIV; 2019 Nov; 6(11):e760-e768. PubMed ID: 31585836
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of baseline CD4 cell count at linkage to HIV care and at initiation of antiretroviral therapy on mortality in HIV-positive adult patients in Rwanda: a nationwide cohort study.
    Nsanzimana S; Remera E; Kanters S; Forrest JI; Ford N; Condo J; Binagwaho A; Bucher H; Thorlund K; Vitoria M; Mills EJ
    Lancet HIV; 2015 Sep; 2(9):e376-84. PubMed ID: 26423551
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mortality in patients with HIV-1 infection starting antiretroviral therapy in South Africa, Europe, or North America: a collaborative analysis of prospective studies.
    Boulle A; Schomaker M; May MT; Hogg RS; Shepherd BE; Monge S; Keiser O; Lampe FC; Giddy J; Ndirangu J; Garone D; Fox M; Ingle SM; Reiss P; Dabis F; Costagliola D; Castagna A; Ehren K; Campbell C; Gill MJ; Saag M; Justice AC; Guest J; Crane HM; Egger M; Sterne JA
    PLoS Med; 2014 Sep; 11(9):e1001718. PubMed ID: 25203931
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outcomes in patients waiting for antiretroviral treatment in the Free State Province, South Africa: prospective linkage study.
    Ingle SM; May M; Uebel K; Timmerman V; Kotze E; Bachmann M; Sterne JA; Egger M; Fairall L;
    AIDS; 2010 Nov; 24(17):2717-25. PubMed ID: 20935554
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antiretroviral treatment outcomes amongst older adults in a large multicentre cohort in South Africa.
    Fatti G; Mothibi E; Meintjes G; Grimwood A
    PLoS One; 2014; 9(6):e100273. PubMed ID: 24949879
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Uptake of antiretroviral therapy and male circumcision after community-based HIV testing and strategies for linkage to care versus standard clinic referral: a multisite, open-label, randomised controlled trial in South Africa and Uganda.
    Barnabas RV; van Rooyen H; Tumwesigye E; Brantley J; Baeten JM; van Heerden A; Turyamureeba B; Joseph P; Krows M; Thomas KK; Schaafsma TT; Hughes JP; Celum C
    Lancet HIV; 2016 May; 3(5):e212-20. PubMed ID: 27126488
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Population-wide differentials in HIV service access and outcomes in the Western Cape for men as compared to women, South Africa: 2008 to 2018: a cohort analysis.
    Osler M; Cornell M; Ford N; Hilderbrand K; Goemaere E; Boulle A
    J Int AIDS Soc; 2020 Jun; 23 Suppl 2(Suppl 2):e25530. PubMed ID: 32589367
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Attrition when providing antiretroviral treatment at CD4 counts >500cells/μL at three government clinics included in the HPTN 071 (PopART) trial in South Africa.
    Bock P; Fatti G; Ford N; Jennings K; Kruger J; Gunst C; Louis F; Grobbelaar N; Shanaube K; Floyd S; Grimwood A; Hayes R; Ayles H; Fidler S; Beyers N;
    PLoS One; 2018; 13(4):e0195127. PubMed ID: 29672542
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of immediate initiation of antiretroviral therapy on risk of severe bacterial infections in HIV-positive people with CD4 cell counts of more than 500 cells per μL: secondary outcome results from a randomised controlled trial.
    O'Connor J; Vjecha MJ; Phillips AN; Angus B; Cooper D; Grinsztejn B; Lopardo G; Das S; Wood R; Wilkin A; Klinker H; Kantipong P; Klingman KL; Jilich D; Herieka E; Denning E; Abubakar I; Gordin F; Lundgren JD;
    Lancet HIV; 2017 Mar; 4(3):e105-e112. PubMed ID: 28063815
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Implementation and outcomes of dolutegravir-based first-line antiretroviral therapy for people with HIV in South Africa: a retrospective cohort study.
    Dorward J; Sookrajh Y; Khubone T; van der Molen J; Govender R; Phakathi S; Lewis L; Bottomley C; Maraj M; Lessells RJ; Naidoo K; Butler CC; Van Heerden R; Garrett N
    Lancet HIV; 2023 May; 10(5):e284-e294. PubMed ID: 37001536
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognosis of patients with HIV-1 infection starting antiretroviral therapy in sub-Saharan Africa: a collaborative analysis of scale-up programmes.
    May M; Boulle A; Phiri S; Messou E; Myer L; Wood R; Keiser O; Sterne JA; Dabis F; Egger M;
    Lancet; 2010 Aug; 376(9739):449-57. PubMed ID: 20638120
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Who starts antiretroviral therapy in Durban, South Africa?... not everyone who should.
    Bassett IV; Regan S; Chetty S; Giddy J; Uhler LM; Holst H; Ross D; Katz JN; Walensky RP; Freedberg KA; Losina E
    AIDS; 2010 Jan; 24 Suppl 1(Suppl 1):S37-44. PubMed ID: 20023438
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalent and incident tuberculosis are independent risk factors for mortality among patients accessing antiretroviral therapy in South Africa.
    Gupta A; Wood R; Kaplan R; Bekker LG; Lawn SD
    PLoS One; 2013; 8(2):e55824. PubMed ID: 23418463
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.